StockData
Ocular Therapeutix, Inc logo

Ocular Therapeutix, Inc (OCUL) stock

OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)

Close on Nov 17, 2026Market cap $1.32BP/E –Yield –

Earnings

Ocular Therapeutix's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 4, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$12.90M
-11.0% on a year earlier
EPS, Q3 FY2026
-$0.42
-$0.38 a year earlier
Latest guidance
Reaffirmed
Nov 14, 2024 · 1 item

Quarterly results

Revenue and earnings per share from each of Ocular Therapeutix's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 4, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 9, 2026before the open$12.90M-11.0%-$0.42Release
Q2 FY2026ended Jun 30, 2026Aug 3, 2026before the open$13.50M0.0%-$0.35Release
Q1 FY2026ended Mar 31, 2026May 5, 2026before the open$10.80M+0.9%-$0.40Release
Q4 FY2025ended Dec 31, 2025Feb 5, 2026before the open$13.30M-22.2%-$0.29Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025before the open$14.50M-5.8%-$0.38Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025before the open$13.50M-17.7%-$0.39Release
Q1 FY2025ended Mar 31, 2025May 5, 2025before the open$10.70M-27.7%-$0.38Release
Q4 FY2024ended Dec 31, 2024Mar 3, 2025before the open$17.10M+15.5%-$0.29Release
Q3 FY2024ended Sep 30, 2024Nov 14, 2024before the open$15.40M+2.0%-$0.22Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024before the open$16.40M+7.9%-$0.26Release
Q1 FY2024ended Mar 31, 2024May 7, 2024after the close$14.80M+10.4%-$0.49Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Ocular Therapeutix guided for has been reported

Guidance history

Every forecast Ocular Therapeutix put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 14, 2024total net revenues for DEXTENZAFY2024$62.00M – $67.00MReaffirmed
Aug 7, 2024total net revenues for DEXTENZAFY2024$62.00M – $67.00MNew
Nov 7, 2023DEXTENZA net product revenueFY2023$55.00M – $60.00MReaffirmed
Aug 7, 2023DEXTENZA net product revenueFY2023$55.00M – $60.00MReaffirmed
May 8, 2023Net product revenueFY2023$55.00M – $60.00MReaffirmed
Mar 6, 2023Net product revenueFY2023$55.00M – $60.00MNew
Nov 7, 2022Total net product revenueFY2022$48.00M – $52.00MLowered
Aug 8, 2022Total net product revenueFY2022$55.00M – $60.00MReaffirmed
May 9, 2022Total net product revenueFY2022$55.00M – $60.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Ocular Therapeutix filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. News
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. News

See a number that looks wrong?